NASDAQ:AGIO

Agios Pharmaceuticals Stock Predictions

Healthcare > Biotechnology

Invest in AGIO

$39.05

-0.480 (-1.21%)

At Close: Jul 11, 2025

Currently predicting for Mon, 14 Jul 2025

Trading levels for AGIO

Full Access. No Commitment. 14 Days Free!

Long & Short-Term Golden Star Lists

AI Stock Analysis Powered by GPT-4o*

Top 5 Candidates on Every List

Premium Lists

Ad-FREE Browsing

Advanced Stock Screener

GET STARTED!

Already have an account? Sign In Here

Fibonacci Support & Resistance Levels

Level	Price
R3	40.33	3.29%
R2	39.88	2.12%
R1	39.59	1.40%
Price	39.05
S1	38.68	-0.94%
S2	38.40	-1.66%
S3	37.94	-2.83%

Accumulated Volume Support & Resistance Levels

Level	Price
R3	0	-
R2	39.53	1.23%
R1	39.07	0.0512%
Price	39.05
S1	34.41	-11.88%
S2	32.63	-16.44%
S3	31.84	-18.46%

AGIO Predictions History

2 years ago
JS predicted that AGIO for 2023-06-08 is going $26.86 (0.98%)

2 years ago
PredictionBot.Kathy predicted that AGIO for 2023-06-08 is going $26.64 (0.13%)

2 years ago
PredictionBot.Warren predicted that AGIO for 2023-06-08 is going $26.78 (0.69%)

6 years ago
NameNotImportant predicted that AGIO for 2019-04-29 is going $56.29 (-1.42%)

8 years ago
IM2Here predicted that AGIO for 2017-01-10 is going $38.00 (-11.17%)

Rank:

ABOUT AGIOS PHARMACEUTICALS

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RYTM $62.29	39.19%	Jun 25
NOV $12.25	11.67%	Jun 04
TENB $32.20	1.13%	Jun 02
G GTM $9.57	6.58%	Jun 02
TAC $8.90	28.20%	May 12

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by